Literature DB >> 12915552

Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

M Mpandi1, L A Otten, C Lavanchy, H Acha-Orbea, D Finke.   

Abstract

Mouse mammary tumor virus (MMTV) infects the host via mucosal surfaces and exploits the host immune system for systemic spread and chronic infection. We have tested a neutralizing rat monoclonal antibody specific for the retroviral envelope glycoprotein gp52 for its efficiency in preventing acute and chronic mucosal and systemic infection. The antibody completely inhibits the superantigen response and chronic viral infection following systemic or nasal infection. Surprisingly however, the antibody only partially inhibits the early infection of antigen-presenting cells in the draining lymph node. Despite this initially inefficient protection from infection, superantigen-specific B- and T-cell responses and systemic viral spread are abolished, leading to complete clearance of the retroviral infection and hence interruption of the viral life cycle. In conclusion, systemic neutralizing monoclonal antibodies can provide an efficient protection against chronic retroviral amplification and persistence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915552      PMCID: PMC187390          DOI: 10.1128/jvi.77.17.9369-9377.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Structure and permeability differ in subepithelial villus and Peyer's patch follicle capillaries.

Authors:  C H Allan; J S Trier
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

2.  Suppressed murine mammary tumor virus (MuMTV) expression in RIII female mice treated neonatally with goat antiserum to MuMTV.

Authors:  A Frensdorff; A Wald
Journal:  J Natl Cancer Inst       Date:  1978-08       Impact factor: 13.506

3.  Cytotoxic T cell clone-specific monoclonal antibodies used to select clonotypic antigen-specific cytotoxic T cells.

Authors:  H Acha-Orbea; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1985-01       Impact factor: 5.532

Review 4.  Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex.

Authors:  J W Kappler; U Staerz; J White; P C Marrack
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

5.  Virus envelope-based peptide vaccines against virus-induced mammary tumors.

Authors:  A S Dion; J J Knittel; S T Morneweck
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

6.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.

Authors:  R Nusse; H E Varmus
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

7.  Systemic antibodies can inhibit mouse mammary tumor virus-driven superantigen response in mucosa-associated lymphoid tissues.

Authors:  D Velin; G Fotopoulos; J P Kraehenbuhl; H Acha-Orbea
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.

Authors:  W Held; A N Shakhov; S Izui; G A Waanders; L Scarpellino; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7).

Authors:  W Held; A N Shakhov; G Waanders; L Scarpellino; R Luethy; J P Kraehenbuhl; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Inhibition of mouse mammary tumor virus-induced T cell responses in vivo by antibodies to an open reading frame protein.

Authors:  H Acha-Orbea; L Scarpellino; A N Shakhov; W Held; H R MacDonald
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV).

Authors:  James S Lawson; Brian Salmons; Wendy K Glenn
Journal:  Front Oncol       Date:  2018-01-22       Impact factor: 6.244

Review 2.  Catching viral breast cancer.

Authors:  James S Lawson; Wendy K Glenn
Journal:  Infect Agent Cancer       Date:  2021-06-10       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.